Ipragliflozin L-Proline structure
|
Common Name | Ipragliflozin L-Proline | ||
---|---|---|---|---|
CAS Number | 951382-34-6 | Molecular Weight | 519.58200 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C26H30FNO7S | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of Ipragliflozin L-ProlineIpragliflozin (L-Proline) is a highly potent and selective SGLT2 inhibitor with an IC50 of 2.8 nM; little and NO potency for SGLT1/3/4/5/6. |
Name | (2S,3R,4R,5S,6R)-2-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-6-(hydroxymethyl)oxane-3,4,5-triol,(2S)-pyrrolidine-2-carboxylic acid |
---|---|
Synonym | More Synonyms |
Description | Ipragliflozin (L-Proline) is a highly potent and selective SGLT2 inhibitor with an IC50 of 2.8 nM; little and NO potency for SGLT1/3/4/5/6. |
---|---|
Related Catalog | |
Target |
IC50 value: 2.8 nM (SGLT2)[1][2]. |
In Vitro | Ipragliflozin (L-Proline) potently and selectively inhibits human, rat, and mouse SGLT2 at nanomolar ranges and exhibits stability against intestinal glucosidases[3]. |
In Vivo | Ipragliflozin (L-Proline) shows good pharmacokinetic properties following oral dosing, and dose-dependently increases urinary glucose excretion, which lasts for over 12 h in normal mice [3]. Oral administration of ipragliflozin increases urinary glucose excretion in a dose-dependent manner, an effect which is significant at doses of 0.3 mg/kg or higher and lasts over 12 h[4]. Single administration of ipragliflozin dose-dependently increases urinary glucose excretion, reduces blood glucose and plasma insulin levels, and improves glucose intolerance [5]. |
References |
Molecular Formula | C26H30FNO7S |
---|---|
Molecular Weight | 519.58200 |
Exact Mass | 519.17300 |
PSA | 167.72000 |
LogP | 2.29790 |
Storage condition | 2-8℃ |
ASP-1941 |
Ipragliflozin L-proline |
UNII-M6N3GK48A4 |
Ipragliflozin (L-Proline) |